Evidence map›Paper›PMID 33194608›Full record

ReviewFrontiers in oncology2020

Long Noncoding RNAs, New Critical Regulators in Cancer Immunity.

Minjie Wu, Peifen Fu, Lei Qu, Jian Liu, Aifu Lin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Crosstalk of ubiquitin system and non-coding RNA in fibrosis.International journal of biological sciences · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma.International journal of molecular sciences · 2022
    Review
  17. Article
  18. High expression of lncRNAOncology letters · 2022
    Article
  19. Tumor immune microenvironment lncRNAs.Briefings in bioinformatics · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Minjie WuBreast Center of the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Peifen FuBreast Center of the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Lei QuMOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou, China.
Jian LiuReproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, Durham, NC, United States.
Aifu LinBreast Center of the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNNational Institute of Environmental Health Sciences · USZhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play crucial roles in various aspects of cellular functions. Recent studies have revealed that lncRNAs are critical players in the immune system by modulating immune cell differentiation and functions, particularly in cancer immunity. Here we systematically summarize how lncRNAs are involved in different processes of the cancer immunity cycle, including immune cell differentiation, proliferation, trafficking, and infiltration. Moreover, the limitations of the current understanding of lncRNA's functions in cancer immunity are described, such as the complexity of the cancer immunity system, the inclusive functions of lncRNAs in this system, and the associated immune response. In sum, the comprehensive investigation of the roles of lncRNAs in cancer immunity aids in cancer diagnosis and therapies.

Indexed as

cancercancer immunitycombined therapyimmunotherapylncRNA

Identifiers

PMID33194608
PMCPMC7662117
OpenAlexW3094829604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.